

## PATENT ASSIGNMENT

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Pulmagen Therapeutics (Inflammation) Limited	11/05/2012
RECEIVING PARTY DATA	
Name:	Chiesi Farmaceutici S.p.A.
Street Address:	Via Palermo, 26/A
City:	Parma
State/Country:	ITALY
Postal Code:	43122
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	13613952
CORRESPONDENCE DATA	
Fax Number:	7034132220
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	(703) 413-3000
Email:	kHUDSON@OBLON.COM
Correspondent Name:	Oblon, Spivak, et al.
Address Line 1:	1940 Duke Street
Address Line 4:	Alexandria, VIRGINIA 22314
ATTORNEY DOCKET NUMBER:	402528US68
NAME OF SUBMITTER:	Karen L. Hudson
Total Attachments: 2 source=402528 Pulmagen#page1.tif source=402528 Pulmagen#page2.tif	

OP \$40.00 13613952

ASSIGNMENT

WHEREAS, Pulmagen Therapeutics (Inflammation) Limited having a place of business at The Coach House, Grenville Court, Britwell Road, Burnham, Slough SL1 8DF, United Kingdom, a corporation organized and existing under the laws of the United Kingdom, is a joint owner with Chiesi Farmaceutici S.p.A., by assignment, of the application for letters patent of the United States of America Application No. 13/613,952, filed September 13, 2012; and

WHEREAS, Chiesi Farmaceutici S.p.A. having a place of business at Via Palermo, 26/A, 43122 Parma, Italy, a corporation organized and existing under the laws of the Country of Italy (hereinafter referred to as "ASSIGNEE"), is desirous of acquiring the entire right, title and interest in and to said application for letters patent and the invention described therein;

NOW, THEREFORE, in consideration of the sum of FIVE DOLLARS (\$5.00) and other valuable consideration, the receipt of which is hereby acknowledged, Pulmagen Therapeutics (Inflammation) Limited by these presents do sell, assign, and transfer unto said ASSIGNEE the entire right, title and interest for the territory of the United States of America in and to the aforesaid application for letters patent and the invention described therein and in and to any and all Letters Patent which may be granted therefor and in and to any and all divisions, continuations, substitutions and renewals thereof.


Pulmagen Therapeutics (Inflammation) Limited hereby authorizes and requests the Patent Office Officials in the United States and its territorial possessions to issue any and all of said Letters Patent, when granted, to said ASSIGNEE as the assignee of the

entire right, title and interest in and to the same, for the sole use and behoof of said ASSIGNEE, its successors and assigns, to the full end of the term for which said Letters Patent may be granted.

IN TESTIMONY WHEREOF, Pulmagen Therapeutics (Inflammation) Limited, has caused these presents to be signed by its officer hereunto duly authorized.

PULMAGEN THERAPEUTICS  
(INFLAMMATION) LIMITED

Date: 5 November 2011

By:   
Name: Colin Knudsen  
Title: DIRECTOR